Alzheimer's and Autism Breakthroughs

[Guest guest]

_____

From: autismparentsupport

[mailto:autismparentsupport ] On Behalf Of Nagla and Alvin

Sent: Thursday, November 08, 2007 12:56 PM

ascc2 ; autismparentsupport ; 'DFW-mafea'

Subject: [autismparentsupport] FW: [abmd] Researchers Present Alzheimer's and

Autism Breakthroughs

-----Original Message-----

From: abmd [mailto:abmd ] On Behalf Of

Wutsername@...

Source: <http://www.newswise.com/institutions/view/?id=3418> Mount Sinai

Medical Center

Released: Wed 07-Nov-2007, 10:50 ET

Researchers Present Alzheimer’s and Autism Breakthroughs

Libraries

Medical News

Keywords

ALZHEIMER'S, AUTISM, DISEASE, BRAIN, GRAPE, SEED, RED, WINE, PINE, CONE,

CABERNET, SAUVIGNON, MUSCADINE, POLYPHENOL, COGNITIVE, DEMENTIA, PERSONALIZED,

MEDICINE

Contact Information

Available for logged-in reporters only

Description

At The Society for Neuroscience annual meeting, Dr. Giulio Pasinetti,

M.D., Ph.D., Professor of Psychiatry and Neuroscience, Geriatrics and Adult

Development and Director of the Center of Excellence for Research in

Complementary and Alternative Medicine in Alzheimer's disease at Mount Sinai

presented the following new breakthrough research findings for Alzheimer’s

disease and other brain disorders.

<http://www.newswise.com/images/tp.gif>

<http://www.newswise.com/images/tp.gif>

Newswise — At The Society for Neuroscience annual meeting, Dr. Giulio

Pasinetti, M.D., Ph.D., Professor of Psychiatry and Neuroscience, Geriatrics and

Adult Development and Director of the Center of Excellence for Research in

Complementary and Alternative Medicine in Alzheimer's disease at Mount Sinai

School of Medicine in New York presented the following new breakthrough research

findings for Alzheimer’s disease and other brain disorders.

Grape Seed Extract Prevents Alzheimer’s Disease

A recent study in Dr. Pasinetti’s laboratory at Mount Sinai explored a

commercially-available atural AZ grape seed extract as a novel alternative

to moderate red wine consumption to prevent Alzheimer’s disease. Dr. Pasinetti

showed that the naturally derived atural AZ grape seed extract is an

effective agent for the prevention of Alzheimer’s disease memory loss and

brain degeneration in a mouse model of Alzheimer’s disease.

Dr. Pasinetti's research on the atural AZ grape seed extract is part of a

growing push to identify and develop more effective natural treatments for

Alzheimer's disease. atural AZ revealed to be an effective agent in

reducing β-amyloid in brain cells. Since abnormally processed beta-amyloid has

been identified as playing a key role in Alzheimer's disease pathogenesis,

particularly in respect to cognitive deterioration, Dr. Pasinetti’s discovery

suggests that atural AZ may be a useful currently available agent to

prevent or treat Alzheimer’s disease memory loss by reducing beta-amyloid in

the brain.

Daily Moderate Consumptions of a Red Muscadine Wine Prevents Cognitive Decline

Researchers at Mount Sinai continue to explore whether other red wines might

provide similar benefits in AD prevention and/or therapy. In the present study

using the Tg2576 mouse AD model, they assessed the potential benefit of

long-term, daily moderate consumptions of the red wine, Muscadine (Vitis

rotundifolia), in AD prevention. Dr. Pasinetti confirmed that under this

treatment paradigm, the daily Muscadine intake by Tg2576 mice is equivalent to

moderate daily wine consumption of one 5-ounze drink per women and two drinks

for men. Similar to their observation with Cabernet Sauvignon, they found that

moderate Muscadine wine consumption significantly attenuated age-dependent

development of Aβ neuropathology and cognitive dysfunction in Tg2576 mice.

Their evidence suggested that the polyphenol components in Muscadine wine are

the bioactive components responsible for attenuating cognitive impairment in

Tg2576 mice, in part, by interfering with the formation of high molecular weight

(HMW) Aβ-oligomers, which are directly implicated in cognitive dysfunction.

Mount Sinai’s studies strengthen the hypothesis that moderate red wine

consumption may delay (or prevent) AD onset. Moreover, these studies highlight a

promising new mechanism by which polyphenolic compounds from red wine, and

perhaps from other dietary sources might be developed as AD preventive and/or

therapeutic measures.

NIC5-15 a Natural Pine-Cones Derived Compound with Anti-Diabetic Properties

Prevents Alzheimer’ Disease - Type Cognitive Deterioration

Recent epidemiological and experimental evidence suggest that attenuation or

prevention of diabetic conditions may reduce the incidence of Alzheimer’s

disease. Consistent with this evidence, studies in Dr. Pasinetti’s laboratory

suggest that insulin “re-sensitization†in experimental mouse models of

Alzheimer’s disease may slow down the onset and eventually the progression of

Alzheimer’ disease. Recent evidence in Mount Sinai’s lab suggests that

NIC-15, a traditional insulin sensitizer herbal agent that occurs in pine tree

components (among other plants or vegetables), can mitigate Alzheimer’s

disease type neuropathology in transgenic models of Alzheimer’s disease

cognitive deterioration. Based on this observation, Dr. Pasinetti laboratory,

decided to continue to explore the mechanisms through which treatment of

diabetic AD-mice with NIC5-15 in mouse models may beneficially attenuates

Alzheimer’s disease type neuropathology.

They report that 5-months old diabetic Tg2576 mice treated for 6 months with

NIC5-15 by incorporation of the drug into the drinking water significantly

attenuated Alzheimer’s disease type cognitive deterioration coincidental with

attenuation diabetic conditions. Most interestingly they found that NIC5-15

improved cognitive performance in insulin-resistant mice that develop AD-type

neuropathology through mechanism involving inhibition of Alzheimer’s disease

type amyloid neuropathology. The lab also found that a mechanisms through which

NIC5-15 may attenuate Alzheimer’s disease type conditions is through the

inhibitions of an enzyme also known as γ-secretase, which is involved in

abnormal generation of amyloid in the brain of Alzheimer’s disease cases.

Thus, characterization of NIC5-15 preventing abnormal β-amyloid generation will

help in the identification of future, novel disease modifying - pharmacological

treatments for Alzheimer's disease. Dr. Pasinetti’s group also found that the

inhibition of the γ-secretase NIC-15 was highly safe and rather selective in

influencing only β-amyloid, since y-secretase activity may in same cases also

influence the activity of certain protective proteins also known as “Notchâ€

which are protein necessary for brain cell survival. These Mount Sinai studies

suggest that NIC5-15, a traditional anti-diabetic herbal agent that occurs in

pine tree components (among other plants or vegetables), can mitigate AD

cognitive deterioration. Based on this exciting evidence Dr. Pasinetti is

currently assessing the effects of NIC5-15 in patients with mild to moderately

severe Alzheimer’s disease dementia.

Personalized Medicine in Autistic Spectrum Disorder

Autism spectrum disorders often remain unrecognized and undiagnosed until, or

after late preschool age due to the lack of appropriate and selective screening

procedures in young children, particularly among toddlers. Development of

clinically accessible molecular signatures may improve disease diagnosis at a

young age and promote early-individualized treatment, which may ultimately

improve the outcome for autistic children and their families. Using a

combination of microRNA (miRNA) and proteomic technology platforms, Dr.

Pasinetti’s laboratory at Mount Sinai used novel molecular signatures as

potential practical and accurate diagnostic assay for Autism spectrum disorders.

Dr. Pasinetti reports the identification of two sets of miRNA in circulating

peripheral blood monocyte cells (PBMC) which selectively and redundantly target

and influence the activity of gene products previously implicated in abnormal

brain structural/behavioral abnormalities and mitochondrial activities in high

functioning autistic spectrum disorder subjects. The development of clinically

accessible molecular signatures such as these identified miRNA may improve

disease diagnosis at a young age and promote early-individualized treatment,

which may ultimately improve the outcome for autistic children and their

families.

Dr. Pasinetti anticipates that his work will lead to earlier interventions and

more specific treatments predicated on the individual’s specific biochemical

fingerprint. This is in stark contrast to current medical practice. Personalized

medicine offers the alluring promise and potential of uncovering the largely

‘unseen’ details in autistic spectrum disorders causality and selective

response to drug treatments.

_____

<http://www.newswise.com/about/policy/#copyright> © 2007 Newswise. All Rights

Reserved.

_____

Email and AIM finally together. You've gotta check out free AOL Mail

<http://o.aolcdn.com/cdn.webmail.aol.com/mailtour/aol/en-us/index.htm?ncid=AOLAO\

F00020000000970> !

[Guest guest]

I really am not seeing the breakthrough on autism. Spell it out for

me, what are they saying works?

>

>

>

>

>

> _____

>

> From: autismparentsupport

[mailto:autismparentsupport ] On Behalf Of Nagla and

Alvin

> Sent: Thursday, November 08, 2007 12:56 PM

> ascc2 ;

autismparentsupport ; 'DFW-mafea'

> Subject: [autismparentsupport] FW: [abmd] Researchers Present

Alzheimer's and Autism Breakthroughs

>

>

>

>

>

> -----Original Message-----

> From: abmd [mailto:abmd ] On Behalf

Of Wutsername@...

>

>

>

>

> Source: <http://www.newswise.com/institutions/view/?id=3418> Mount

Sinai Medical Center

>

>

>

> Released: Wed 07-Nov-2007, 10:50 ET

>

>

> Researchers Present Alzheimer’s and Autism Breakthroughs

>

>

> Libraries

> Medical News

>

>

>

> Keywords

> ALZHEIMER'S, AUTISM, DISEASE, BRAIN, GRAPE, SEED, RED, WINE, PINE,

CONE, CABERNET, SAUVIGNON, MUSCADINE, POLYPHENOL, COGNITIVE,

DEMENTIA, PERSONALIZED, MEDICINE

>

>

> Contact Information

>

> Available for logged-in reporters only

>

>

> Description

>

> At The Society for Neuroscience annual meeting, Dr. Giulio

Pasinetti, M.D., Ph.D., Professor of Psychiatry and Neuroscience,

Geriatrics and Adult Development and Director of the Center of

Excellence for Research in Complementary and Alternative Medicine in

Alzheimer's disease at Mount Sinai presented the following new

breakthrough research findings for Alzheimer’s disease and other

brain disorders.

>

>

>

>

>

>

>

> <http://www.newswise.com/images/tp.gif>

>

>

>

>

>

> <http://www.newswise.com/images/tp.gif>

>

>

>

>

> Newswise †" At The Society for Neuroscience annual meeting, Dr.

Giulio Pasinetti, M.D., Ph.D., Professor of Psychiatry and

Neuroscience, Geriatrics and Adult Development and Director of the

Center of Excellence for Research in Complementary and Alternative

Medicine in Alzheimer's disease at Mount Sinai School of Medicine in

New York presented the following new breakthrough research findings

for Alzheimer’s disease and other brain disorders.

>

> Grape Seed Extract Prevents Alzheimer’s Disease

> A recent study in Dr. Pasinetti’s laboratory at Mount Sinai

explored a commercially-available atural AZ grape seed extract

as a novel alternative to moderate red wine consumption to prevent

Alzheimer’s disease. Dr. Pasinetti showed that the naturally

derived atural AZ grape seed extract is an effective agent for

the prevention of Alzheimer’s disease memory loss and brain

degeneration in a mouse model of Alzheimer’s disease.

>

> Dr. Pasinetti's research on the atural AZ grape seed extract

is part of a growing push to identify and develop more effective

natural treatments for Alzheimer's disease. atural AZ revealed

to be an effective agent in reducing β-amyloid in brain cells. Since

abnormally processed beta-amyloid has been identified as playing a

key role in Alzheimer's disease pathogenesis, particularly in respect

to cognitive deterioration, Dr. Pasinetti’s discovery suggests that

atural AZ may be a useful currently available agent to prevent

or treat Alzheimer’s disease memory loss by reducing beta-amyloid

in the brain.

>

> Daily Moderate Consumptions of a Red Muscadine Wine Prevents

Cognitive Decline

> Researchers at Mount Sinai continue to explore whether other red

wines might provide similar benefits in AD prevention and/or therapy.

In the present study using the Tg2576 mouse AD model, they assessed

the potential benefit of long-term, daily moderate consumptions of

the red wine, Muscadine (Vitis rotundifolia), in AD prevention. Dr.

Pasinetti confirmed that under this treatment paradigm, the daily

Muscadine intake by Tg2576 mice is equivalent to moderate daily wine

consumption of one 5-ounze drink per women and two drinks for men.

Similar to their observation with Cabernet Sauvignon, they found that

moderate Muscadine wine consumption significantly attenuated age-

dependent development of Aβ neuropathology and cognitive dysfunction

in Tg2576 mice. Their evidence suggested that the polyphenol

components in Muscadine wine are the bioactive components responsible

for attenuating cognitive impairment in Tg2576 mice, in part, by

interfering with the formation of high molecular weight (HMW) Aβ-

oligomers, which are directly implicated in cognitive dysfunction.

Mount Sinai’s studies strengthen the hypothesis that moderate red

wine consumption may delay (or prevent) AD onset. Moreover, these

studies highlight a promising new mechanism by which polyphenolic

compounds from red wine, and perhaps from other dietary sources might

be developed as AD preventive and/or therapeutic measures.

>

> NIC5-15 a Natural Pine-Cones Derived Compound with Anti-Diabetic

Properties Prevents Alzheimer’ Disease - Type Cognitive

Deterioration

> Recent epidemiological and experimental evidence suggest that

attenuation or prevention of diabetic conditions may reduce the

incidence of Alzheimer’s disease. Consistent with this evidence,

studies in Dr. Pasinetti’s laboratory suggest that insulin “re-

sensitization†in experimental mouse models of Alzheimer’s

disease may slow down the onset and eventually the progression of

Alzheimer’ disease. Recent evidence in Mount Sinai’s lab suggests

that NIC-15, a traditional insulin sensitizer herbal agent that

occurs in pine tree components (among other plants or vegetables),

can mitigate Alzheimer’s disease type neuropathology in transgenic

models of Alzheimer’s disease cognitive deterioration. Based on

this observation, Dr. Pasinetti laboratory, decided to continue to

explore the mechanisms through which treatment of diabetic AD-mice

with NIC5-15 in mouse models may beneficially attenuates

Alzheimer’s disease type neuropathology.

>

> They report that 5-months old diabetic Tg2576 mice treated for 6

months with NIC5-15 by incorporation of the drug into the drinking

water significantly attenuated Alzheimer’s disease type cognitive

deterioration coincidental with attenuation diabetic conditions. Most

interestingly they found that NIC5-15 improved cognitive performance

in insulin-resistant mice that develop AD-type neuropathology through

mechanism involving inhibition of Alzheimer’s disease type amyloid

neuropathology. The lab also found that a mechanisms through which

NIC5-15 may attenuate Alzheimer’s disease type conditions is

through the inhibitions of an enzyme also known as γ-secretase,

which is involved in abnormal generation of amyloid in the brain of

Alzheimer’s disease cases. Thus, characterization of NIC5-15

preventing abnormal β-amyloid generation will help in the

identification of future, novel disease modifying - pharmacological

treatments for Alzheimer's disease. Dr. Pasinetti’s group also

found that the inhibition of the γ-secretase NIC-15 was highly safe

and rather selective in influencing only β-amyloid, since y-

secretase activity may in same cases also influence the activity of

certain protective proteins also known as “Notch†which are

protein necessary for brain cell survival. These Mount Sinai studies

suggest that NIC5-15, a traditional anti-diabetic herbal agent that

occurs in pine tree components (among other plants or vegetables),

can mitigate AD cognitive deterioration. Based on this exciting

evidence Dr. Pasinetti is currently assessing the effects of NIC5-15

in patients with mild to moderately severe Alzheimer’s disease

dementia.

>

> Personalized Medicine in Autistic Spectrum Disorder

> Autism spectrum disorders often remain unrecognized and undiagnosed

until, or after late preschool age due to the lack of appropriate and

selective screening procedures in young children, particularly among

toddlers. Development of clinically accessible molecular signatures

may improve disease diagnosis at a young age and promote early-

individualized treatment, which may ultimately improve the outcome

for autistic children and their families. Using a combination of

microRNA (miRNA) and proteomic technology platforms, Dr.

Pasinetti’s laboratory at Mount Sinai used novel molecular

signatures as potential practical and accurate diagnostic assay for

Autism spectrum disorders. Dr. Pasinetti reports the identification

of two sets of miRNA in circulating peripheral blood monocyte cells

(PBMC) which selectively and redundantly target and influence the

activity of gene products previously implicated in abnormal brain

structural/behavioral abnormalities and mitochondrial activities in

high functioning autistic spectrum disorder subjects. The development

of clinically accessible molecular signatures such as these

identified miRNA may improve disease diagnosis at a young age and

promote early-individualized treatment, which may ultimately improve

the outcome for autistic children and their families.

>

> Dr. Pasinetti anticipates that his work will lead to earlier

interventions and more specific treatments predicated on the

individual’s specific biochemical fingerprint. This is in stark

contrast to current medical practice. Personalized medicine offers

the alluring promise and potential of uncovering the largely

‘unseen’ details in autistic spectrum disorders causality and

selective response to drug treatments.

>

> _____

>

> <http://www.newswise.com/about/policy/#copyright> © 2007

Newswise. .

>

>

>

> _____

>

> Email and AIM finally together. You've gotta check out free AOL

Mail <http://o.aolcdn.com/cdn.webmail.aol.com/mailtour/aol/en-

us/index.htm?ncid=AOLAOF00020000000970> !

>

>

>

>

>

>